[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553795":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":45,"responsibleParty":62,"collaborators":24,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":24,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":24,"studyType":78,"phases":79,"briefSummary":82,"conditions":83,"keywords":24,"overallStatus":48,"whyStopped":24,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"New Valley University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients will receive dexmedetomidine","ACTIVE_COMPARATOR","Patients will receive dexmedetomidine (Precedex®; 200 µg\u002F2 ml; at one µg\u002Fkg loading dose over 10 minutes followed by a 0.5 µg\u002Fkg\u002Fhr. maintenance dose for 48 hours Dexmedetomidine will be diluted in normal saline at a 4 µg\u002F ml concentration",[13],"Drug: Dexmedetomidine",{"label":15,"type":10,"description":16,"interventionNames":17},"Patients will receive ketamine","Patients will receive ketamine at one mg\u002Fkg IV loading dose over 10 minutes, then a continuous infusion starting at 300 µg \u002Fkg\u002Fhr over 48 hours",[18],"Drug: Ketamine",[20,25],{"type":21,"name":22,"description":9,"armGroupLabels":23,"otherNames":24},"DRUG","Dexmedetomidine",[9],null,{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Ketamine","patients Will receive ketamine",[15],[30],{"name":31,"affiliation":32,"role":33},"Ahmed Ismail Abdel Sabour, MD","NewValley University","PRINCIPAL_INVESTIGATOR",[35,41],{"name":36,"role":37,"phone":38,"phoneExt":39,"email":40},"Ahmed Ismail ABDEL sabour, MD","CONTACT","01097845491","2","ahmed_ismail87@med.nvu.edu.eg",{"name":42,"role":37,"phone":43,"phoneExt":39,"email":44},"ayman Mohamed Fawzy, Msc","01028697487","fawzyayman629@med.nvu.edu.eg",[46],{"facility":47,"status":48,"city":49,"state":24,"zip":24,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"asyut University","RECRUITING","Asyut","Egypt","EG",{"type":53,"coordinates":54},"Point",[55,56],31.18368,27.18096,{"lat":56,"lon":55},[59],{"name":60,"role":37,"phone":61,"phoneExt":24,"email":24},"Alaa attia, professur","01099923117",{"type":33,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Ahmed Ismail Abdelsabour","lecture of anesthesia and ICU","100553795","phase-1-effects-of-dexmedetomidine-versus-ketamine-on-inflammatory-response-and-hemodynamic-in-patients-100553795",false,"NCT06490731","Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients","Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients With Intraabdominal Sepsis: A Randomized Controlled Study","Inclusion Criteria:\n\n* • Adult patients admitted to ICU after ileus surgery (perforated viscus, infarcted bowel, strangulated hernia, anastomotic leakage, diverticulitis, and intestinal obstruction), and who will be expected to require postoperative sedation and ventilation.\n\n  * Abdominal sepsis was determined as organ dysfunction with a substantial change in overall SOFA score (2) ≥ 2 points because of intra-abdominal sepsis.\n\nExclusion Criteria:\n\n* • Known allergy to ketamine, dexmedetomidine,\n\n  * Confirmed pregnancy,\n  * Heart failure (class 3 or 4 of the New York Heart Association),\n  * Renal failure (RIFLE classification),\n  * Liver failure (manifested by serum total protein concentration \\\u003C3 g\u002Fdl and total bilirubin \\>5 mg\u002Fdl)\n  * Known or suspected brain death.\n  * Patients who receive neuromuscular blockers during the first 48 hours of ICU admission will also be excluded.","ALL","18 Years","70 Years",{"count":76,"type":77},2,"ESTIMATED","INTERVENTIONAL",[80,81],"PHASE1","PHASE2","Inflammatory response and hemodynamic response in patients with intraabdominal sepsis and Effects of Dexmedetomidine versus ketamine on it .",[84],"Haemodynamic Rebound","2026-05-02",{"date":87,"type":88},"2026-05-07","ACTUAL",{"date":90,"type":88},"2026-04-01",{"date":92,"type":77},"2026-10-01",{"name":5,"class":6},1]